Skip to main content

Table 3 Example of the REMARK profile illustrated using data from a study of expression of epithelial membrane protein-2 in patients with endometrial adenocarcinoma [158].

From: Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration

a) Patients, treatment and variables
136 Patients with endometrial adenocarcinoma assessed for eligibility, 37 excluded (33 no informative immune histochemistry, 4 without clinical information)
99 Patients included, stages IA to IVB
Formalin fixed, paraffin embedded endometrial tissue samples, Department of Pathology, UCLA Los Angeles, USA
Marker (and how was the marker handled in analysis?) M = epithelial membrane protein-2
Immunoreactive score obtained by multiplying subscores for intensity (0 to 3+) and distribution of immunoreactivity (0 to 4+) grouped as negative (score 0), weak (1 to 3) or moderate-to-strong (4 to 12)
Outcomes: DFS (97 patients, 42 events), OS (99 patients, 32 events)
Further variables: v1 = age, v2 = ER, v3 = PR, v4 = vascular invasion, v5 = stage, v6 = histology, v7 = grade
b) Statistical analyses of survival outcomes
  DFS OS   
Aim Patients Events Patients Events Variables considered Results/remarks
A1: Univariable 97 42 99 32 M, v1-v7 Figure 3, Figure 4, Table 2, Table 3
       DFS: except v1 all significant
       OS: all significant
A2: Multivariable 97 42 99 32 DFS: M, v2-v7 Table 4, Table 5
      OS: M, v1-v7 In multivariable analysis: all significant in A1, then stepwise selection
       Variables in final models: DFS: M, v5, v6; OS: v4, v6, v7 (M is not included)
  1. DFS: disease-free survival; ER: estrogen receptor; M: epithelial protein; PR: progesterone receptor; OS: overall survival.